| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX5 |
| Uniprot No | O60225 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-229aa |
| 氨基酸序列 | MNGDDAFVRRPRVGSQIPQKMQKHPWRQVCDRGIHLVNLSPFWKVGREPASSIKALLCGRGEARAFDDIAKYFSEKEWEKMKASEKIIYVYMKRKYEAMTKLGFKATLPPFMRNKRVADFQGNDFDNDPNRGNQVEHPQMTFGRLQGIFPKITPEKPAEEGNDSKGVPEASGPQNNGKQLRPSGKLNTSEKVNKTSGPKRGKHAWTHRVRERKQLVIYEEISDPQEDDE |
| 预测分子量 | 53.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SSX5重组蛋白的3篇参考文献示例(注：部分内容为模拟概括，实际文献可能需要进一步核实)：
---
1. **标题**：**"Recombinant SSX5 Protein Induces Antitumor Immunity in Mouse Models of Synovial Sarcoma"**
**作者**：Smith A, et al.
**摘要**：研究报道了SSX5重组蛋白在大肠杆菌中的高效表达与纯化方法，并证明其在小鼠滑膜肉瘤模型中能激活特异性CD8+ T细胞免疫应答，提示其作为肿瘤疫苗的潜力。
2. **标题**：**"Structural and Functional Analysis of SSX5 Recombinant Protein in Chromatin Remodeling"**
**作者**：Johnson R, et al.
**摘要**：通过体外重组表达SSX5蛋白，结合质谱和共沉淀实验，揭示了SSX5与Polycomb抑制复合物(PRC1)的相互作用，探讨其在表观遗传调控中的潜在作用机制。
3. **标题**：**"Development of an SSX5-Specific ELISA for Cancer Diagnosis Using Recombinant Antigens"**
**作者**：Wang L, et al.
**摘要**：利用SSX5重组蛋白作为抗原开发新型血清学检测方法，在滑膜肉瘤患者中验证了高诊断敏感性，为临床无创检测提供新策略。
---
**备注**：上述文献为示例性质，实际研究中建议通过PubMed或Web of Science以“SSX5 recombinant protein”“SSX5 cancer antigen”等关键词检索最新文献。若SSX5直接研究有限，可扩展至SSX家族蛋白(如SSX1/SSX2)的重组表达相关研究作为参考。
The SSX5 protein, a member of the SSX (synovial sarcoma X breakpoint) gene family, is a cancer-testis antigen (CTA) predominantly expressed in germline cells and certain malignancies. Discovered in the context of synovial sarcoma, SSX genes gained attention due to their role in chromosomal translocations with SS18 (SYT), forming oncogenic fusion proteins (SS18-SSX) that drive tumorigenesis. The SSX family comprises 10 paralogs (SSX1-9 and SSXB), sharing conserved domains, including a KRAB-associated protein 1 (KAP1)-binding motif and an SSX repression domain, which influence transcriptional regulation and chromatin remodeling.
SSX5. like other SSX proteins, exhibits restricted expression in normal tissues (primarily testis) but is aberrantly activated in cancers, including melanoma, myeloma, and carcinomas. This tumor-specific expression classifies it as a potential immunotherapeutic target. Recombinant SSX5 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified antigens for research and clinical applications. Its recombinant form enables studies on immune recognition, antigen processing, and T-cell response activation, supporting vaccine development and adoptive T-cell therapies.
Research highlights SSX5’s role in modulating epigenetic pathways and promoting cell proliferation, though its exact oncogenic mechanisms remain under investigation. Recombinant SSX5 is also utilized in serological assays to detect autoantibodies in cancer patients, aiding diagnosis and prognosis. Challenges include its low immunogenicity and heterogeneity across tumors, prompting strategies like multi-epitope targeting or combination therapies. Current studies focus on optimizing recombinant SSX5 for clinical use, emphasizing its dual role as a biomarker and therapeutic target in precision oncology.
×
